Prophylactic antibiotics for cystic fibrosis

Area of Science:

• Pulmonary Medicine
• Infectious Diseases
• Pediatrics

Background:

• Cystic fibrosis (CF) leads to airway obstruction, recurrent infections, and progressive lung disease.
• Preventive antibiotic use in CF aims to reduce infection burden but carries risks of adverse effects and antibiotic resistance.
• Current evidence on long-term prophylactic antibiotic efficacy and safety in CF is limited.

Purpose of the Study:

• To compare continuous oral antibiotic prophylaxis with no prophylaxis in cystic fibrosis patients.
• To evaluate the effectiveness of prophylaxis on bacterial isolates, treatment needs, lung function, and survival.
• To assess the adverse effects associated with prophylactic antibiotic use.

Main Methods:

• Systematic review of randomized or pseudo-randomized controlled trials.
• Inclusion criteria: continuous oral prophylactic antibiotics (≥1 year) vs. intermittent therapy in CF patients.
• Outcomes assessed: lung function, nutrition, survival, additional antibiotic treatment, pathogen isolation, and adverse reactions.

Main Results:

• Three studies (177 patients, ages 0-7) were included.
• Reduced prevalence of Staphylococcus aureus in respiratory secretions with anti-staphylococcal prophylaxis.
• No significant effect on other pathogens, infant lung function after one year, or survival.
• Trend towards lower Pseudomonas aeruginosa isolation rates with prophylaxis over three years.

Conclusions:

• Early-onset anti-staphylococcal antibiotic prophylaxis (infancy to age three) may offer benefits in CF.
• Insufficient evidence exists for the efficacy and safety of prophylaxis in older children, adults, or for durations exceeding three years.
• Further research is needed to determine long-term outcomes and optimal use of prophylactic antibiotics in CF management.